peptides vaccine

2 trials

Sponsors

Iwate Medical University School of Medicine department of Obstetrics and Gynecology, Iwate Medical University School of Medicine department of Obastetrics and Gynecology

Conditions

advanced/recurrent cervical cancer with the conditions of unremoval by surgery, or refractory, chemo-resistant disease.

Phase 1

Tumor specific vaccination therapy for advanced/recurrent cervical cancer using HLA-A*2402 restricted Specific Epitope Peptides Cocktail derived from Tumor genom/Tumor related Angiogenetic factors genom

Active, not recruitingJPRN-UMIN000003902

Iwate Medical University School of Medicine department of Obstetrics and Gynecologyadvanced/recurrent cervical cancer with the conditions of unremoval by surgery, or refractory, chemo-resistant disease.

Start: 2010-07-01Target: 30Updated: 2026-06-29

Tumor specific vaccination therapy for advanced/recurrent cervical cancer using HLA-A*0201 restricted Specific Epitope Peptides Cocktail derived from Tumor genom/Tumor related Angiogenetic factors genom

Active, not recruitingJPRN-UMIN000003903

Iwate Medical University School of Medicine department of Obastetrics and Gynecologyadvanced/recurrent cervical cancer with the conditions of unremoval by surgery, or refractory, chemo-resistant disease.

Start: 2014-03-31Target: 30Updated: 2026-06-29